163 related articles for article (PubMed ID: 38695532)
21. Catalytically Active Metal-Organic Frameworks Elicit Robust Immune Response to Combination Chemodynamic and Checkpoint Blockade Immunotherapy.
Wang X; Luo J; Wang J; Cao J; Hong Y; Wen Q; Zeng Y; Shi Z; Ma G; Zhang T; Huang P
ACS Appl Mater Interfaces; 2023 Feb; 15(5):6442-6455. PubMed ID: 36700645
[TBL] [Abstract][Full Text] [Related]
22. Phase-Transformation Nanoparticle-Mediated Sonodynamic Therapy: An Effective Modality to Enhance Anti-Tumor Immune Response by Inducing Immunogenic Cell Death in Breast Cancer.
Si Y; Yue J; Liu Z; Li M; Du F; Wang X; Dai Z; Hu N; Ju J; Gao S; Wang X; Yuan P
Int J Nanomedicine; 2021; 16():1913-1926. PubMed ID: 33707946
[TBL] [Abstract][Full Text] [Related]
23. Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
Liu D; Chen B; Mo Y; Wang Z; Qi T; Zhang Q; Wang Y
Nano Lett; 2019 Oct; 19(10):6964-6976. PubMed ID: 31518149
[TBL] [Abstract][Full Text] [Related]
24. Immunogenic Cell Death Augmented by Manganese Zinc Sulfide Nanoparticles for Metastatic Melanoma Immunotherapy.
Li Z; Chu Z; Yang J; Qian H; Xu J; Chen B; Tian T; Chen H; Xu Y; Wang F
ACS Nano; 2022 Sep; 16(9):15471-15483. PubMed ID: 35981098
[TBL] [Abstract][Full Text] [Related]
25. An ultrasound-activated nanoplatform remodels tumor microenvironment through diverse cell death induction for improved immunotherapy.
Ma J; Yuan H; Zhang J; Sun X; Yi L; Li W; Li Z; Fu C; Zheng L; Xu X; Wang X; Wang F; Yin D; Yuan J; Xu C; Li Z; Peng X; Wang J
J Control Release; 2024 Jun; 370():501-515. PubMed ID: 38703950
[TBL] [Abstract][Full Text] [Related]
26. Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy.
Pan Y; Wu X; Liu L; Zhao C; Zhang J; Yang S; Pan P; Huang Q; Zhao XZ; Tian R; Rao L
Adv Healthc Mater; 2024 May; 13(13):e2400068. PubMed ID: 38320299
[TBL] [Abstract][Full Text] [Related]
27. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
28. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
29. Dual-Responsive Nanomedicine Activates Programmed Antitumor Immunity through Targeting Lymphatic System.
Xiao H; Li X; Liang S; Yang S; Han S; Huang J; Shuai X; Ren J
ACS Nano; 2024 Apr; 18(17):11070-11083. PubMed ID: 38639726
[TBL] [Abstract][Full Text] [Related]
30. Immunogenic Cell Death Inducing Fluorinated Mitochondria-Disrupting Helical Polypeptide Synergizes with PD-L1 Immune Checkpoint Blockade.
Jeong SD; Jung BK; Ahn HM; Lee D; Ha J; Noh I; Yun CO; Kim YC
Adv Sci (Weinh); 2021 Apr; 8(7):2001308. PubMed ID: 33854870
[TBL] [Abstract][Full Text] [Related]
31. STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.
Lemos H; Mohamed E; Huang L; Ou R; Pacholczyk G; Arbab AS; Munn D; Mellor AL
Cancer Res; 2016 Apr; 76(8):2076-81. PubMed ID: 26964621
[TBL] [Abstract][Full Text] [Related]
32. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
Ding Y; Sun Z; Gao Y; Zhang S; Yang C; Qian Z; Jin L; Zhang J; Zeng C; Mao Z; Wang W
Adv Mater; 2021 Aug; 33(34):e2102188. PubMed ID: 34278622
[TBL] [Abstract][Full Text] [Related]
33. Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy.
Liu Z; Liu B; Feng Y; Zhao L; Wang Q; He H; Yin T; Zhang Y; Yang L; Gou J; Tang X
ACS Nano; 2024 Jun; 18(24):15557-15575. PubMed ID: 38837909
[TBL] [Abstract][Full Text] [Related]
34. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
[TBL] [Abstract][Full Text] [Related]
35. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
[TBL] [Abstract][Full Text] [Related]
36. A phenolic based tumor-permeated nano-framework for immunogenic cell death induction combined with PD-L1 immune checkpoint blockade.
Sun X; Zhang J; Xiu J; Zhao X; Yang C; Li D; Li K; Hu H; Qiao M; Chen D; Zhao X
Biomater Sci; 2022 Jul; 10(14):3808-3822. PubMed ID: 35670432
[TBL] [Abstract][Full Text] [Related]
37. Combination of MHI148 Targeted Photodynamic Therapy and STING Activation Inhibits Tumor Metastasis and Recurrence.
Yu H; Chen Q; Zheng M; Wang R; Wang H; Cheng L; Hu Y; Dai M; Du C; Luo W; Tan M; Cao Y; Guo Y; Ran H
ACS Appl Mater Interfaces; 2024 Jun; 16(23):29672-29685. PubMed ID: 38813586
[TBL] [Abstract][Full Text] [Related]
38. Manganese-Enriched Zinc Peroxide Functional Nanoparticles for Potentiating Cancer Immunotherapy.
Zhou M; Liang S; Liu D; Ma K; Yun K; Yao J; Peng Y; Hai L; Zhang Q; Wang Z
Nano Lett; 2023 Nov; 23(22):10350-10359. PubMed ID: 37930173
[TBL] [Abstract][Full Text] [Related]
39. Extracellular matrix-degrading STING nanoagonists for mild NIR-II photothermal-augmented chemodynamic-immunotherapy.
Zhan M; Yu X; Zhao W; Peng Y; Peng S; Li J; Lu L
J Nanobiotechnology; 2022 Jan; 20(1):23. PubMed ID: 34991618
[TBL] [Abstract][Full Text] [Related]
40. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity.
Wang Z; Chen J; Hu J; Zhang H; Xu F; He W; Wang X; Li M; Lu W; Zeng G; Zhou P; Huang P; Chen S; Li W; Xia LP; Xia X
J Clin Invest; 2019 Aug; 129(11):4850-4862. PubMed ID: 31408442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
